RT Journal Article
SR Electronic
T1 Mapping rare protein-coding variants on multi-organ imaging traits
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.16.24317443
DO 10.1101/2024.11.16.24317443
A1 Fan, Yijun
A1 Chen, Jie
A1 Fan, Zirui
A1 Chirinos, Julio
A1 Stein, Jason L.
A1 Sullivan, Patrick F.
A1 Wang, Rujin
A1 Nadig, Ajay
A1 Zhang, David Y.
A1 Huang, Shuai
A1 Jiang, Zhiwen
A1 Guan, Peter Yi
A1 Qian, Xinjie
A1 Li, Ting
A1 Li, Haoyue
A1 Sun, Zehui
A1 Ritchie, Marylyn D.
A1 O’Brien, Joan
A1 Witschey, Walter
A1 Rader, Daniel J.
A1 Li, Tengfei
A1 Zhu, Hongtu
A1 Zhao, Bingxin
YR 2024
UL http://medrxiv.org/content/early/2024/11/18/2024.11.16.24317443.abstract
AB Human organ structure and function are important endophenotypes for clinical outcomes. Genome-wide association studies (GWAS) have identified numerous common variants associated with phenotypes derived from magnetic resonance imaging (MRI) of the brain and body. However, the role of rare protein-coding variations affecting organ size and function is largely unknown. Here we present an exome-wide association study that evaluates 596 multi-organ MRI traits across over 50,000 individuals from the UK Biobank. We identified 107 variant-level associations and 224 gene-based burden associations (67 unique gene-trait pairs) across all MRI modalities, including PTEN with total brain volume, TTN with regional peak circumferential strain in the heart left ventricle, and TNFRSF13B with spleen volume. The singleton burden model and AlphaMissense annotations contributed 8 unique gene-trait pairs including the association between an approved drug target gene of KCNA5 and brain functional activity. The identified rare coding signals elucidate some shared genetic regulation across organs, prioritize previously identified GWAS loci, and are enriched for drug targets. Overall, we demonstrate how rare variants enhance our understanding of genetic effects on human organ morphology and function and their connections to complex diseases.Competing Interest StatementR.W. is a current employee and/or stockholder of Regeneron Genetics Center or Regeneron Pharmaceuticals. Other authors declare no competing interests.Funding StatementResearch reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number RF1AG082938 (B.Z. and H.Z.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study has also been partially supported by funding from the Purdue University Statistics Department, Department of Statistics and Data Science at the University of Pennsylvania, Wharton Dean's Research Fund, Analytics at Wharton, and Perelman School of Medicine CCEB Innovation Center Grant (B.Z.). The study has also been partially supported by the National Institute On Aging of the National Institutes of Health under Award Numbers U01AG079847 and R01AR082684 (H.Z.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The individual-level data used in the present study have been openly available from the UK Biobank (https://www.ukbiobank.ac.uk/) study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe individual-level data used in this study can be obtained from UK Biobank (https://www.ukbiobank.ac.uk/). Other datasets in this paper include: Genebass (https://app.genebass.org/), GWAS summary statistics for imaging traits in BIG-KP (https://bigkp.org/), dbNSFP v.4.5a (https://sites.google.com/site/jpopgen/dbNSFP), the Therapeutic Target Database (https://idrblab.net/ttd/), and the GTEx dataset v8 (https://gtexportal.org/home/). The full ExWAS summary statistics generated in this study will be deposited in Zenodo upon publication.